1 Regnault C, Soursac M, Roch-Arveiller M, Postaire E, Hazebroucq G. Pharmacokinetics of superoxide dismutase in rats after oral administration. Biopharm Drug Dispos . 1996;17:165–74.
2 Giri SN, Misra HP. Fate of superoxide dismutase in mice following oral route of administration. Med Biol . 1984;62:285–9.
3 Regnault C, Roch-Arveiller M, Tissot M, et al. Effect of encapsulation on the anti-inflammatory properties of superoxide dismutase after oral administration. Clin Chim Acta . 1995;240:117–27.
4 Delanian S, Martin M, Bravard A, Luccioni C, Lefaix JL. Cu/Zn superoxide dismutase modulates phenotypic changes in cultured fibroblasts from human skin with chronic radiotherapy damage. Radiother Oncol . 2001;58:325–31.
5 Delanian S, Baillet F, Huart J, Lefaix JL, Maulard C, Housset M. Successful treatment of radiation-induced fibrosis using liposomal Cu/Zn superoxide dismutase: clinical trial. Radiother Oncol . 1994;32:12–20.
6 Housset M, Baillet F, Michelson AM, Puget K. Action of liposomal superoxide dismutase on measurable radiation-induced fibrosis. Ann Med Interne (Paris) . 1989;140:365–7.
7 Lefaix JL, Delanian S, Leplat JJ, et al. Radiation-induced cutaneo-muscular fibrosis (III): major therapeutic efficacy of liposomal Cu/Zn superoxide dismutase [in French]. Bull Cancer . 1993;80:799–807.
8 Ratcheva I, Stefanova Z, Vesselinova A, Nikolova S, Kujumdjieva A, Neychev H. Treatment of adjuvant arthritis in mice with yeast superoxide dismutase. Pharmazie . 2000;55:533–7.
9 Vorauer-Uhl K, Furnschlief E, Wagner A, et al. Reepithelialization of experimental scalds effected by topically applied superoxide dismutase: controlled animal studies. Wound Repair Regen . 2002;10:366–71.
10 Flanagan SW, Anderson RD, Ross MA, Oberley LW. Overexpression of manganese superoxide dismutase attenuates neuronal death in human cells expressing mutant (G37R) Cu/Zn-superoxide dismutase. J Neurochem . 2002;81:170–7.
11 Gallagher IM, Jenner P, Glover V, Clow A. CuZn-superoxide dismutase transgenic mice: no effect on longevity, locomotor activity and 3H-mazindol and 3H-spiperone binding over 19 months. Neurosci Lett . 2000;289:221–3.
12 Huang TT, Carlson EJ, Gillespie AM, Shi Y, Epstein CJ. Ubiquitous overexpression of CuZn superoxide dismutase does not extend life span in mice. J Gerontol A Biol Sci Med Sci . 2000;55:B5–9.
13 Parkes TL, Elia AJ, Dickinson D, Hilliker AJ, Phillips JP, Boulianne GL. OMIM extension of Drosophila lifespan by overexpression of human SOD1 in motorneurons. Nat Genet . 1998;19:171–4.
14 Davis JM, Rosenfeld WN, Richter SE, et al. The effects of multiple doses of recombinant human CuZn superoxide dismutase (rhSOD) in premature infants with respiratory distress syndrome (RDS). Pediatr Res . 1999;45:193A (Abstract no.1129).
15 Davis JM, Richter SE, Biswas S, et al. Long-term follow-up of premature infants treated with prophylactic, intratracheal recombinant human CuZn superoxide dismutase. J Perinatol . 2000;4:213–216.
16 Rosenfeld WN, Davis JM, Parton L, et al. Safety and pharmacokinetics of recombinant human superoxide dismutase administered intratracheally to premature neonates with respiratory distress syndrome. Pediatrics . 1996;97:811–817.
- Reviewer: EBSCO CAM Review Board
- Review Date: 09/2014 -
- Update Date: 09/18/2014 -
This content is reviewed regularly and is updated when new and relevant evidence is made available. This information is neither intended nor implied to be a substitute for professional medical advice. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with questions regarding a medical condition.
Copyright © EBSCO Publishing
All rights reserved.